IBB News and Press, iShares Biotechnology ETF From 05/16/23

2023-05-16 19:09:57 ET Summary Many US-listed biotech companies are likely to trade cheaply relative to their prospects as a result of concerns about the stability of the US banking system and the risk of a recession. I believe biotech investors should consider a "Buy" rating on A...

2023-05-16 18:55:18 ET Summary HSCT-TMA BLA Resubmission: Omeros plans to resubmit a BLA for narsoplimab, potentially gaining approval by Q2 2024. IgAN Trial Progress: Top-line results for the phase 3 ARTEMIS trial on narsoplimab for IgAN are expected in Q3 2023. Solid Financi...

2023-05-16 16:26:55 ET Summary Acquisition: Sobi acquires CTI BioPharma for ~$1.7 billion, an 85% premium, aligning with Sobi's focus on hematology. Confidence: Main shareholder Investor AB's agreement to rights issue signifies deal confidence; no overlapping drugs between SOBI an...

2023-05-16 14:35:00 ET Summary Both the Consumer Price Index and Producer Price Index data for April confirmed that the strong but lumpy disinflationary trend continues. The US is now at a point where the Fed funds rate exceeds inflation. Historically that has signaled the end of ...

2023-05-15 13:44:44 ET Shares of the SPDR S&P Biotech ETF ( NYSEARCA: XBI ) moved up to a new 3-month trading high on Monday afternoon as the exchange traded fund picked up 3.5% on the day. Moreover, the fund opened trading at $85.72 a share and moved up to $88.20 a...

2023-05-12 03:54:34 ET Summary The private domestic sector balance decreased by $295+ billion in April 2023 with headwinds in all sectors. Bank credit retraction was -$62+ billion as more loans were repaid or written off than were created. The four-month drop continues. The se...

2023-05-11 12:29:00 ET Summary In the first three months of 2023, the company posted $237.6 million in revenue, up 28.2% from the previous quarter. In addition to the Merck deal, OPKO received a $7 million payment from Vifor in Q1 2023, thanks to the German price approval for Raya...

2023-05-10 15:28:29 ET Summary Among US-listed biotech stocks with promising prospects, investors should consider holding a position in Omega Therapeutics, Inc. as the company calls 2023 a pivotal year. Omega Therapeutics is a clinical-stage developer of controllers of the epigene...

2023-05-10 07:05:51 ET Summary Since publishing the last article on PTC Therapeutics, the company's share price has risen 31.28%, outperforming the iShares Biotechnology ETF and the S&P 500. Overall, risdiplam is the company's third-highest-grossing medicine, with sales of CHF...

2023-05-05 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...